Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05423743 · ClinicalTrials.gov registry record · NA
INSPIRE Trial for Abdominal Infections
A NA study, sponsored by Harvard Pilgrim Health Care.
- Completed
- Registry status
- NA
- Development phase
- 198,480
- Enrollment target
NCT05423743: Completed NA study, sponsored by Harvard Pilgrim Health Care.
NCT05423743 is a NA study that has completed, run by Harvard Pilgrim Health Care. The registered enrollment target is 198,480 participants, above the 1,400-participant average among 58,714 other NA trials with a reported enrollment target (14077% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05423743, a NA study, has completed, sponsored by Harvard Pilgrim Health Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 198,480 participants
- Enrollment target
Study Summary
The INSPIRE Abdominal Infection Trial is a cluster-randomized controlled trial of HCA Healthcare hospitals comparing routine empiric antibiotic stewardship practices with real-time, precision medicine computerized physician order entry (CPOE) smart prompts providing the probability that a non-critically ill adult admitted with abdominal infection is infected with a resistant pathogen. Note: enrolled "subjects" represent 102 individual HCA Healthcare hospitals that have been randomized into 92 clusters. Hospitals were grouped into the same randomization cluster if they shared campuses or antibiotic stewardship staff.
Primary Outcome
Days-of-Therapy is a standardized national measure for antibacterial use in hospitals that counts each different antibiotic administered on each calendar day as one day of therapy, regardless of doses given. Extended-spectrum days-of-therapy per empiric day is defined as the summed number of different extended-spectrum antibiotics received per patient each calendar day, beginning at admission. If an admission is less than 3 days, only the number of days the patient is admitted will contribute t
Interventions
- OTHER Arm 1: Routine Care
- OTHER Arm 2: INSPIRE Stewardship Bundle for Abdominal Infection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198,480 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2025-05-09 |
| Phase | NA |
What the finished NCT05423743 record still lists
NCT05423743 is an interventional study that assigns participants to a tested intervention. Its 198,480 participants enrollment target places it among the larger protocols in the corpus, above the 1,400-participant average among 58,714 other NA trials with a reported enrollment target (14077% higher).
The record links to 0 conditions, and to 2 interventions - of which Arm 1: Routine Care is the first listed.
NCT05423743 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05423743 about?
NCT05423743 is a clinical study titled "INSPIRE Trial for Abdominal Infections". The INSPIRE Abdominal Infection Trial is a cluster-randomized controlled trial of HCA Healthcare hospitals comparing routine empiric antibiotic stewardship practices with real-time, precision medicine computerized physician order entry (CPOE) smart prompts providing the probability that a non-critic...
What is the current status of trial NCT05423743?
This trial is currently completed. It is a NA study. The enrollment target is 198,480 participants. The study started on 2023-01-01. Estimated completion is 2025-05-09.
What interventions are being tested in trial NCT05423743?
The interventions under investigation include: Arm 1: Routine Care (OTHER), Arm 2: INSPIRE Stewardship Bundle for Abdominal Infection (OTHER).
Who is sponsoring clinical trial NCT05423743?
This trial is sponsored by Harvard Pilgrim Health Care, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05423743's enrollment target sits among peer trials
198,480 1st of 2000 higher than 2,000 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06090578 · 180,000 participants · NA
TabCAT Brain Health Assessment in Primary Care
- NCT06917339 · 156,000 participants
Retrospective Analyses of TrakStar Database
- NCT06232551 · 152,000 participants · NA
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
- NCT04735835 · 250,000 participants · NA
Personalized Responses to Dietary Composition Trial 3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI